Abstract
Background: Oesophageal adenocarcinoma (OAC) is a lethal cancer with an overall 5-year survival of <20%. Given the presence of a pre-invasive disease stage, also known as Barrett’s oesophagus (BO), and the availability of minimally invasive treatments for BO-related neoplasia, it is thought that early detection is the best strategy to improve patient outcomes. Clinical guidelines recommend endoscopic screening in patients with symptoms of acid reflux and additional risk factors. This strategy is flawed by the cost and invasiveness of endoscopy as well as by the fact that a significant proportion of OAC patients deny a history of reflux symptoms. Summary: New research on the use of epidemiologic and clinical data has allowed the creation of risk-prediction algorithms to identify the population at risk. In addition, newer less-invasive devices such as transnasal endoscopy, Cytosponge, volumetric laser endomicroscopy, and volatile organic compounds are emerging as promising options to allow screening in the primary care setting. Finally, there is an opportunity to intervene at the pre-invasive stage with pharmacological strategies to reduce the risk burden. Key Messages: In this review, we provide a critical appraisal of the different screening approaches and chemopreventive strategies and a guide to readers on how to implement research evidence in clinical practice.
References
1.
Cancer research UK (CRUK) oesophageal cancer statistics. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/oesophageal-cancer#heading-Two.
2.
Ronkainen
J
, Aro
P
, Storskrubb
T
, Johansson
SE
, Lind
T
, Bolling–Sternevald
E
, Prevalence of Barrett’s esophagus in the general population: an endoscopic study
. Gastroenterology
. 2005
;129
(6
):1825
–31
.3.
Westhoff
B
, Brotze
S
, Weston
A
, McElhinney
C
, Cherian
R
, Mayo
MS
, The frequency of Barrett’s esophagus in high-risk patients with chronic GERD
. Gastrointest Endosc
. 2005 Feb
;61
(2
):226
–31
.4.
Hamade
N
, Weng
G
, Desai
M
, Chandrasekar
VT
, Dasari
C
, Kennedy
K
, Significant decline in the prevalence of Barrett’s esophagus among patients with gastroesophageal reflux disease
. Dis Esophagus
. 2021 May 22
;34
(5
):doaa13
.5.
Desai
TK
, Krishnan
K
, Samala
N
, Singh
J
, Cluley
J
, Perla
S
, The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s oesophagus: a meta-analysis
. Gut
. 2012
;61
(7
):970
–6
.6.
Fitzgerald
RC
, di Pietro
M
, Ragunath
K
, Ang
Y
, Kang
JY
, Watson
P
, British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus
. Gut
. 2014
;63
(1
):7
–42
.7.
Shaheen
NJ
, Falk
GW
, Iyer
PG
, Gerson
LB
. ACG clinical guideline: diagnosis and management of Barrett’s esophagus
. Am J Gastroenterol
. 2016
;111
(1
):30
.8.
Siegel
RL
, Miller
KD
, Jemal
A
, Jemal
A
. Cancer statistics, 2016
. CA Cancer J Clin
. 2021
;66
(1
):7
–30
. .9.
Cooper
GS
, Yuan
Z
, Chak
A
, Rimm
AA
. Association of prediagnosis endoscopy with stage and survival in adenocarcinoma of the esophagus and gastric cardia
. Cancer
. 2002
;95
(1
):32
–8
. .10.
Bhat
SK
, McManus
DT
, Coleman
HG
, Johnston
BT
, Cardwell
CR
, McMenamin
Ú
, Oesophageal adenocarcinoma and prior diagnosis of Barrett's oesophagus: a Population-Based Study
. Gut
. 2015
;64
(1
):20
–5
.11.
Verbeek
RE
, Leenders
M
, Ten Kate
FJ
, van Hillegersberg
R
, Vleggaar
FP
, van Baal
JW
, Surveillance of Barrett’s esophagus and mortality from esophageal adenocarcinoma: a Population-Based Cohort Study
. Am J Gastroenterol
. 2014 Aug
;109
(8
):1215
–22
.12.
Chak
A
, Faulx
A
, Eng
C
, Grady
W
, Kinnard
M
, Ochs-Balcom
H
, Gastroesophageal reflux symptoms in patients with adenocarcinoma of the esophagus or cardia
. Cancer
. 2006 Nov 1
;107
(9
):2160
–6
.13.
Vaughan
TL
, Fitzgerald
RC
. Precision prevention of oesophageal adenocarcinoma
. Nat Rev Gastroenterol Hepatol
. 2015 Apr
;12
(4
):243
–8
. .14.
Rubenstein
JH
, McConnell
D
, Waljee
AK
, Metko
V
, Nofz
K
, Khodadost
M
, Validation and comparison of tools for selecting individuals to screen for Barrett’s esophagus and early neoplasia
. Gastroenterology
. 2020
;158
(8
):2082
–92
.15.
Juhasz
A
, Mittal
SK
, Lee
TH
, Deng
C
, Chak
A
, Lynch
HT
. Prevalence of Barrett esophagus in first-degree relatives of patients with esophageal adenocarcinoma
. J Clin Gastroenterol
. 2011 Nov-Dec
;45
(10
):867
–71
. .16.
Shariff
MK
, Varghese
S
, O’Donovan
M
, Abdullahi
Z
, Liu
X
, Fitzgerald
RC
, Pilot Randomized Crossover Study comparing the efficacy of transnasal disposable endosheath with standard endoscopy to detect Barrett’s esophagus
. Endoscopy
. 2016 Feb
;48
(2
):110
–6
.17.
Ross-Innes
CS
, Debiram-Beecham
I
, O'Donovan
M
, Walker
E
, Varghese
S
, Lao-Sirieix
P
, Evaluation of a minimally invasive cell sampling device coupled with assessment of trefoil factor 3 expression for diagnosing Barrett's esophagus: a Multi-Center Case–Control Study
. PLoS Med
. 2015
;12
(1
):e1001780
.18.
Fitzgerald
RC
, di Pietro
M
, O'Donovan
M
, Maroni
R
, Muldrew
B
, Debiram-Beecham
I
, Cytosponge-trefoil factor 3 versus usual care to identify Barrett’s oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial
. Lancet
. 2020
;396
(10247
):333
–44
.19.
Gehrung
M
, Crispin-Ortuzar
M
, Berman
AG
, O’Donovan
M
, Fitzgerald
RC
, Markowetz
F
. Triage-driven diagnosis of Barrett’s esophagus for early detection of esophageal adenocarcinoma using deep learning
. Nat Med
. 2021
;27
(5
):833
–41
.20.
Gora
MJ
, Sauk
JS
, Carruth
RW
, Gallagher
KA
, Suter
MJ
, Nishioka
NS
, Tethered capsule endomicroscopy enables less invasive imaging of gastrointestinal tract microstructure
. Nat Med
. 2013
;19
(2
):238
–40
.21.
van der Putten
J
, Struyvenberg
M
, de Groof
J
, Scheeve
T
, Curvers
W
, Schoon
E
, Deep principal dimension encoding for the classification of early neoplasia in Barrett’s esophagus with volumetric laser endomicroscopy
. Comput Med Imaging Graph
. 2020
;80
:101701
.22.
Markar
SR
, Wiggins
T
, Antonowicz
S
, Chin
ST
, Romano
A
, Nikolic
K
, Assessment of a noninvasive exhaled breath test for the diagnosis of oesophagogastric cancer
. JAMA Oncol
. 2018 Jul 1
;4
(7
):970
–6
.23.
Peters
Y
, Schrauwen
RW
, Tan
AC
, Bogers
SK
, de Jong
B
, Siersema
PD
. Detection of Barrett’s oesophagus through exhaled breath using an electronic nose device
. Gut
. 2020
;69
(7
):1169
–172
.24.
Chen
H
, Fang
Y
, Tevebaugh
W
, Orlando
RC
, Shaheen
NJ
, Chen
X
. Molecular mechanisms of Barrett’s esophagus
. Dig Dis Sci
. 2011
;56
(12
):3405
–20
. .25.
Jiang
M
, Li
H
, Zhang
Y
, Yang
Y
, Lu
R
, Liu
K
, Transitional basal cells at the squamous–columnar junction generate Barrett’s oesophagus
. Nature
. 2017
;550
(7677
):529
–33
.26.
Nowicki-Osuch
K
, Zhuang
L
, Jammula
S
, Bleaney
CW
, Mahbubani
KT
, Devonshire
G
, Molecular phenotyping reveals the identity of Barrett’s esophagus and its malignant transition
. Science
. 2021
;373
(6556
):760
–7
.27.
Singh
S
, Garg
SK
, Singh
PP
, Iyer
PG
, El-Serag
HB
. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis
. Gut
. 2014
;63
(8
):1229
–37
. 28.
Hvid-Jensen
F
, Pedersen
L
, Funch-Jensen
P
, Drewes
AM
. Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett's oesophagus: a Nationwide Study of 9883 patients
. Aliment Pharmacol Ther
. 2014 May
;39
(9
):984
–91
. 29.
Jankowski
JA
, De Caestecker
J
, Love
SB
, Reilly
G
, Watson
P
, Sanders
S
, Esomeprazole and aspirin in Barrett’s oesophagus (AspECT): a randomised factorial trial
. Lancet
. 2018
;392
(10145
):400
–8
.30.
Moayyedi
P
, Eikelboom
JW
, Bosch
J
, Connolly
SJ
, Dyal
L
, Shestakovska
O
, Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin
. Gastroenterology
. 2019 Sep
;157
(3
):682
–91.e2
.31.
Thrift
AP
, Anderson
LA
, Murray
LJ
, Cook
MB
, Shaheen
NJ
, Rubenstein
JH
, Nonsteroidal anti-inflammatory drug use is not associated with reduced risk of barrett’s esophagus
. Am J Gastroenterol
. 2016 Nov
;111
(11
):1528
–35
.32.
Morris
CD
, Armstrong
GR
, Bigley
G
, Green
H
, Attwood
SE
. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence
. Am J Gastroenterol
. 2001 Apr
;96
(4
):990
–6
. 33.
Zhang
S
, Zhang
X
, Ding
X
, Yang
R
, Huang
S
, Kastelein
F
, Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett’s esophagus: a meta-analysis
. Br J Cancer
. 2014
;110
(9
):2378
–88
.34.
Singh
S
, Singh
AG
, Singh
PP
, Murad
MH
, Iyer
PG
. Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: a systematic review and meta-analysis
. Clin Gastroenterol Hepatol
. 2013
;11
(6
):620
–9
. .© 2022 S. Karger AG, Basel
2022
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
